share_log

Takeda Pharmaceutical | 6-K: Takeda intends to rapidly initiate the first global Phase 3 trials of TAK-861, an oral orexin agonist, in narcolepsy type 1 in first half of fiscal year 2024

Takeda Pharmaceutical | 6-K: Takeda intends to rapidly initiate the first global Phase 3 trials of TAK-861, an oral orexin agonist, in narcolepsy type 1 in first half of fiscal year 2024

武田制药 | 6-K:武田制药计划于在2024财年上半年迅速启动口服奥曲肽激动剂TAK-861治疗1型嗜睡症的首批全球3期试验
美股sec公告 ·  02/09 06:09
声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息